

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 September 2023 (14.09.2023)



(10) International Publication Number
WO 2023/172968 A1

(51) International Patent Classification:
A61K 47/68 (2017.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2023/063957

(22) International Filing Date:
08 March 2023 (08.03.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/318,256 09 March 2022 (09.03.2022) US
63/488,269 03 March 2023 (03.03.2023) US

(71) Applicant: **MERCK PATENT GMBH** [DE/DE]; Frankfurter Strasse 250, 64293 Darmstadt (DE).

(72) Inventors; and

(71) Applicants: **MCKENNA, Sean D.** [US/US]; EMD Serono Research and Development Institute, Inc., 45A Middlesex Turnpike, Billerica, Massachusetts 01821 (US). **GROSS, Alec** [US/US]; EMD Serono Research and Development Institute, Inc., 45A Middlesex Turnpike, Billerica, Massachusetts 01821 (US). **MA, Jianguo** [CN/US]; EMD Serono Research and Development Institute, Inc., 45A Middlesex Turnpike, Billerica, Massachusetts 01821 (US). **DOTTERWEICH, Julia** [DE/DE]; Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt (DE). **RASCHE, Nicholas** [DE/DE]; Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt (DE). **SHAN, Min** [DE/DE]; Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt (DE). **AMENDT, Christiane** [DE/DE]; Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt (DE). **ANDERL, Jan** [DE/DE]; Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt (DE). **SLOOT, Willem** [NL/NL]; Merck Healthcare KGaA, Frankfurter Strasse 250, 64293 Darmstadt (DE).

(74) Agent: **BROWN, Thomas W.**; EMD Serono Research and Development Institute, Inc., 45A Middlesex Turnpike, Billerica, Massachusetts 01821 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,

RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: ANTI-GD2 ANTIBODIES, IMMUNOCONJUGATES AND THERAPEUTIC USES THEREOF

(57) Abstract: The invention provides antibodies which bind human GD2 protein, as well as isolated nucleic acids and host cells comprising a sequence encoding said antibodies. The invention also provides immunoconjugates comprising said antibodies linked to a growth-inhibitory agent, and pharmaceutical compositions comprising antibodies or immunoconjugates of the invention. The invention also provides use of the antibodies, immunoconjugates and pharmaceutical compositions of the invention for the treatment of cancer or for diagnostic purposes.

WO 2023/172968 A1